hyccin, regulates the synthesis of phosphatidylinositol 4-phosphate (PtdIns(4)P), a determinant of plasma membrane identity [4] [5] [6] . HCC patient fibroblasts exhibit reduced PtdIns(4)P levels. FAM126A is an intrinsic component of the plasma membrane phosphatidylinositol 4-kinase complex that comprises PI4KIIIα and its adaptors TTC7 and EFR3 (refs 5,7) . A FAM126A-TTC7 co-crystal structure reveals an all-α-helical heterodimer with a large protein-protein interface and a conserved surface that may mediate binding to PI4KIIIα. Absence of FAM126A, the predominant FAM126 isoform in oligodendrocytes, destabilizes the PI4KIIIα complex in mouse brain and patient fibroblasts. We propose that HCC pathogenesis involves defects in PtdIns(4)P production in oligodendrocytes, whose specialized function requires massive plasma membrane expansion and thus generation of PtdIns(4)P and downstream phosphoinositides [8] [9] [10] [11] . Our results point to a role for FAM126A in supporting myelination, an important process in development and also following acute exacerbations in multiple sclerosis [12] [13] [14] .
Phosphoinositides are low-abundance anionic membrane phospholipids that play critical roles in many physiological processes 15, 16 . At the plasma membrane, a major phosphoinositide is PtdIns(4)P, which has direct signalling roles and in addition serves as the precursor of two other plasma membrane-enriched phosphoinositides with major signalling functions in this membrane, PtdIns(4,5)P 2 and PtdIns(3,4,5)P 3 (refs 4,17) . In oligodendrocytes and Schwann cells, these lipids regulate several steps in the biogenesis and maintenance of myelin, including the recruitment of myelin basic protein (MBP) to the plasma membrane by PtdIns(4,5)P 2 and the promotion of myelin growth by PtdIns(3,4,5)P 3 (refs 8-11) .
Phosphorylation of phosphatidylinositol (PtdIns) to generate PtdIns(4)P at the plasma membrane is mediated by PtdIns 4-kinase Type IIIα (PI4KIIIα; Stt4 in yeast) 5, 18, 19 . The properties, targeting mechanisms and regulation of this enzyme have only recently come into focus. Two factors required for its localization at the plasma membrane have been described 5, 7 and structurally characterized 20 : EFR3 and TTC7 (Efr3 and Ypp1 in yeast). To identify additional regulators of PI4KIIIα, we used quantitative interaction proteomics. We immunoprecipitated either stably expressed TTC7B-GFP or GFP, followed by protease digestion and mass spectrometry analysis, to identify candidate TTC7B-binding proteins ( Fig. 1a and Supplementary Table 1) . These experiments identified the known TTC7B interaction partners PI4KIIIα, EFR3A and EFR3B. Among the other hits, two of the most significantly enriched candidates were the paralogous FAM126A, also known as hyccin, and FAM126B, both of which were also identified in similar experiments using EFR3A-GFP or EFR3B-GFP as the bait (Supplementary Fig. 1a ).
Mutations in FAM126A that lead to loss of the FAM126A protein cause a recessive leukoencephalopathy termed hypomyelination and congenital cataract 3 (HCC). Manifestations of this condition, which include progressive neurological impairment, mild to moderate cognitive defects, and peripheral neuropathy, stem from hypomyelination in the central and peripheral nervous systems 3, 21, 22 . No molecular functions or activities have been ascribed to FAM126A, and the cellular and molecular mechanisms of HCC pathogenesis are unknown. Thus, the identification of FAM126A as a potential interaction partner of TTC7 and EFR3 led us to investigate its role in PI4KIIIα complex formation and function as a first step towards understanding whether defects in phosphoinositide metabolism may cause HCC pathology.
We first explored and confirmed the interaction of FAM126A with TTC7, and more generally its association with the PI4KIIIα complex, in co-immunoprecipitation/immunoblot experiments (Fig. 1b) . Two FAM126A immunoreactive species (relative molecular masses of 58,000 (M r 58K) and 47,000 (M r 47K)) were enriched in TTC7B-GFP immunoprecipitates, corresponding to two predicted splice forms of FAM126A ( Supplementary Fig. 1b) . Accordingly, these two bands are absent in tissues from FAM126A knockout (KO) mice ( Supplementary  Fig. 1c ). Given that the longer, M r 58K band represents the main form in mammalian brain ( Supplementary Fig. 1d ), we chose to focus on it in our subsequent studies. We then performed a reciprocal proteomics experiment using FAM126A-GFP-expressing cells to assess whether PI4KIIIα, TTC7 and EFR3 are the main interaction partners of FAM126A. Indeed, all of these proteins were the strongest hits in analogous quantitative proteomics experiments (Fig. 1a and Supplementary Table 1) and were highly enriched in immunoblot analysis of FAM126A-GFP immunoprecipitates (Fig. 1b) .
Examination of the primary amino acid sequence of FAM126A revealed a highly conserved, structured amino-terminal portion (FAM126A-N, residues 1-289) common to both splice forms and a poorly conserved carboxy-terminal tail predicted to be disordered (FAM126A-C, residues 290-521; Fig. 1c ). Co-immunoprecipitation experiments of GFP-tagged full-length FAM126A, FAM126A-N or FAM126A-C with differentially tagged PI4KIIIα, TTC7B and EFR3B revealed an interaction of all of these components with full-length FAM126A and FAM126A-N (Fig. 1d) . Note that the apparent more robust interaction of these proteins with FAM126A-N than with full-length FAM126A (Fig. 1d , lanes 6 and 7) reflects higher levels of FAM126A-N in the total lysate. Interestingly, overexpression of FAM126A-N led to a marked increase in levels of transfected TTC7B in total lysate (Fig. 1d, lane 3) , suggesting a stabilizing interaction between these two proteins, as further confirmed by experiments described below. We next examined whether, as would be expected for a direct TTC7 interactor 5 , FAM126A-N localizes to the plasma membrane when co-expressed with other PI4KIIIα complex subunits. Using confocal microscopy, we found that GFP-tagged FAM126A-N and full-length FAM126A were localized to the cytosol in HeLa and COS-7 cells (Fig. 2a and Supplementary Fig. 2a ). Whereas coexpression of FAM126A-N with EFR3B, the membrane anchor for the PI4KIIIα complex (Fig. 2, bottom) , did not change the FAM126A-N localization (Fig. 2b) , co-expression of FAM126A-N or full-length FAM126A with both EFR3B and TTC7B resulted in a relocalization of FAM126A to the plasma membrane ( Fig. 2c and Supplementary  Fig. 2b ). Further, co-expression of FAM126A-N, TTC7B, EFR3B and PI4KIIIα resulted in co-localization of all four proteins at the plasma membrane in a manner that was dependent on the presence of TTC7B (Fig. 2d,e) . Omission of EFR3B revealed a cytosolic colocalization (but nuclear exclusion) of TTC7B, FAM126A-N and PI4KIIIα (Fig. 2f) . Collectively, these data argue for a central role of TTC7B not only in bridging PI4KIIIα to EFR3B, the plasma membrane anchor, as reported previously 5, 7, 20 , but also in mediating the association of FAM126A to the plasma membrane, consistent with a direct interaction.
The localization experiments did not, however, allow us to conclusively determine whether, at the plasma membrane, FAM126A and PI4KIIIα can bind to TTC7B simultaneously, or, alternatively, whether FAM126A competes with PI4KIIIα for binding to TTC7B. To address this issue, we first confirmed the direct interaction between FAM126A-N and TTC7B by co-expression of the proteins in Escherichia coli and analysis of the resulting complex by sizeexclusion chromatography (Fig. 3a) . The two proteins co-eluted as a heterodimer. Importantly, protein-protein interaction experiments with purified proteins showed that the TTC7B/FAM126A-N subcomplex interacts directly with PI4KIIIα ( Fig. 3b ), ruling out a competition between FAM126A and PI4KIIIα for TTC7 binding.
Given that the TTC7B/FAM126A-N heterodimer bound tightly to PI4KIIIα, we next examined the effects of each of these proteins on the catalytic activity of PI4KIIIα. We purified wild-type (WT) or kinase-dead PI4KIIIα alone or in complex with either TTC7B alone or both TTC7B and FAM126A-N ( Supplementary Fig. 3a) and assessed the relative kinase activity in vitro by monitoring the formation of PtdIns(4)P from PtdIns in the presence of γ 32 P-labelled ATP. The PI4KIIIα/TTC7B complex was about twice as enzymatically active as PI4KIIIα alone, and the PI4KIIIα/TTC7B/FAM126A-N ternary complex was roughly fivefold more active (Fig. 3c) . Thus, both TTC7B and FAM126A seem to play a role in stabilizing the PI4KIIIα fold and/or stimulating the intrinsic enzymatic activity of the kinase.
To obtain further insights into the role of FAM126A in the kinase complex, we determined the crystal structure of the TTC7B/FAM126A-N dimer at 2.9 Å resolution ( Wild-type (WT) or kinase-dead (KD) PI4KIIIα was produced either alone or in complex with TTC7B or TTC7B/FAM126A-N as indicated ( Supplementary  Fig. 3a) , and in vitro lipid kinase activity assays were performed using PtdIns-containing liposomes and γ 32 P-labelled ATP. The extent of PtdIns(4)P formation was assessed by thin-layer chromatography and autoradiography. Two-tailed Student's t-test with unequal variance: * P = 0.0001 (n = 3 independent experiments). Error bars represent standard deviation. Unprocessed original scans of gels are shown in Supplementary Fig. 6 . very C-terminal peptide inserted into the centre of the superhelix (Fig. 4b) . FAM126A-N is globular, except for a long hairpin (residues 121-165) that extends out and wraps around TTC7B (Fig. 4b) . The proteins interact through an unusually large interface (∼6,000 Å 2 total occluded surface area, where >2,000 Å 2 is considered large), indicative of a high-affinity, stable interaction as would be expected if FAM126A is an intrinsic part of the kinase complex (Fig. 4c) .
Interestingly, although the interacting surfaces in both proteins are well conserved in metazoans (Fig. 4c) , the FAM126A-interacting surface of TTC7B is not conserved in fungi (including in Saccharomyces cerevisiae Ypp1; ref. 20) . Indeed, we have not been able to identify a fungal FAM126A homologue, and it is possible that FAM126 is not conserved across eukaryotic evolution but is a modification to the PI4KIIIα system present only in higher eukaryotes. Nevertheless, the overall organization of EFR3, TTC7 and PI4KIIIα within the complex is most likely conserved (Fig. 4d) . Thus, as the yeast homologue of TTC7 interacts with the kinase through conserved surfaces in the C-terminal lobe 20 , we reason that mammalian TTC7 interacts with PI4KIIIα in a similar way. We note that in the TTC7B/FAM126A-N subcomplex there is a conserved surface comprising the C-terminal portion of TTC7B and adjoining FAM126A residues, and we propose that these surfaces together form the binding site for PI4KIIIα in mammals (Fig. 4c) .
The structural data suggest a stabilizing function for FAM126A in the PI4KIIIα complex. To test this hypothesis, we first examined the levels of PI4KIIIα complex components in primary human skin fibroblasts from five HCC patients that are homozygous for either nonsense or missense mutations in FAM126A (refs 3,21,23) . Cells from patients with nonsense mutations were completely devoid of the FAM126A protein (Fig. 5a, lanes 3, 5 and 7) , and cells from patients with missense mutations (L53P and C57R, see Supplementary  Fig. 3c ) exhibited greatly reduced levels of FAM126A (Fig. 5a, lanes 4  and 6) , consistent with the misfolding and near-complete degradation of FAM126A in these cells. Indeed, immunoblot analysis revealed decreases in the levels of PI4KIIIα and its adaptors TTC7A, TTC7B and EFR3A (EFR3B was not detectable in the fibroblasts; Fig. 5a and Supplementary Fig. 4a ), suggesting a general destabilization and degradation of the PI4KIIIα complex components in the absence of FAM126A. Accordingly, reintroduction of GFP-tagged FAM126A into the patient fibroblasts using a lentiviral vector partially rescued this phenotype (Supplementary Fig. 4b ). Although a compensatory increase in FAM126B, a paralogue of FAM126A, was also observed in patient fibroblasts ( Fig. 5a and Supplementary Fig. 4a) , the approximately tenfold lower expression of FAM126B messenger RNA in fibroblasts ( Supplementary Fig. 4c ) may explain why this increase is not sufficient to compensate for lack of FAM126A.
High-performance liquid chromatography (HPLC) analysis of total phosphoinositide content revealed a decrease in total cellular PtdIns(4)P in HCC fibroblasts relative to control fibroblasts (Fig. 5b) , and a specific decrease of the plasma membrane fraction of PtdIns(4)P in HCC fibroblasts relative to control fibroblasts was confirmed by immunofluorescence ( Fig. 5c and Supplementary Fig. 4d ). Thus, FAM126A loss specifically affects PI4KIIIα complex assembly and PI4KIIIα-mediated PtdIns(4)P synthesis at the plasma membrane.
Global KO of PI4KIIIα in several model organisms leads to lethality 5, [24] [25] [26] , whereas loss of FAM126A is permissive of life, although it causes defects in myelination in humans, leading to HCC (ref. 3) . To investigate the potential role of FAM126A in promoting PI4KIIIα function in myelination, we compared the expression levels of PI4KIIIα complex subunits in mouse primary cortical neurons and oligodendrocytes. We found that FAM126A was expressed in both oligodendrocytes and neurons, whereas its paralogue FAM126B was expressed at much lower levels in oligodendrocytes relative to neurons ( Fig. 5d and Supplementary Fig. 4a ). Thus, in principle, a global loss of FAM126A could, in the brain, be more effectively compensated by FAM126B in neurons than in oligodendrocytes and thus more severely affect PI4KIIIα function in the latter cell type.
To support this possibility, we evaluated the levels of PI4KIIIα complex components in brain tissue from FAM126A KO mice 27 . Although these mice do not exhibit an obvious abnormal phenotype or specific defects in myelination as evaluated by light and electron microscopy analysis (Supplementary Fig. 5 ), immunoblot analysis of lysates from total brain and optic nerve (a pure white matter tract) revealed a selective decrease of TTC7A and EFR3A relative to WT (Fig. 5e,f and Supplementary Fig. 4a ). These are the isoforms of TTC7 and EFR3 whose levels are more highly expressed in oligodendrocytes relative to neurons, compared with their respective paralogues TTC7B and EFR3B ( Fig. 5d and Supplementary Fig. 4a ).
These results are further supported by immunoblot analysis of cellular fractions of different lineages that were generated from dissociated brain tissue by affinity purification from WT and FAM126A KO mice. Notably, there was a more pronounced decrease in PI4KIIIα, EFR3A/B and TTC7A/B in cells of the oligodendroglial lineage compared with those of the neuronal lineage ( Supplementary  Fig. 4e ). Taken together, these data connect FAM126A to PI4KIIIα function in the nervous system and implicate the white matter as a region potentially susceptible to PI4KIIIα dysfunction following global loss of FAM126A, pointing to a mechanistic hypothesis for HCC disease pathogenesis. Although it seems surprising that the lack of FAM126A in mice does not produce the neurological phenotype observed in humans, we note that the greater diameter of axons and thickness of the myelin sheath around such axons in humans implies a larger surface area of oligodendrocytes 28, 29 . Thus, a greater demand on the machinery responsible for myelin biogenesis and maintenance in humans may explain their enhanced sensitivity to loss of FAM126A and impaired PtdIns(4)P synthesis.
Interestingly, FAM126A expression was reported to be repressed by activated β-catenin 30 , and canonical Wnt/β-catenin/TCF signalling was recently shown to be a powerful negative regulator of oligodendrocyte differentiation 31 , a step that precedes the massive plasma membrane biogenesis that occurs in myelination. Our data suggest that activation of PI4KIIIα may be an important downstream consequence of the relief of Wnt/β-catenin/TCF signalling that occurs in oligodendrocyte development.
In sum, our results demonstrate that FAM126A (hyccin) is an intrinsic component of the PI4KIIIα complex and an important regulator of PtdIns(4)P production at the plasma membrane, the first step in the synthesis of the bulk of the downstream phosphoinositides PtdIns(4,5)P 2 and PtdIns(3,4,5)P 3 . We further provide evidence for an important role of FAM126A in oligodendrocytes, a cell type whose specialized function is to markedly expand its plasma membrane. PtdIns(4,5)P 2 is implicated in myelin compaction 8, 9 , and PtdIns(3,4,5)P 3 helps drive myelin growth 10, 11 . Collectively, our studies point to impaired production of these phosphoinositides as a mechanism through which absence of FAM126A results in a hypomyelinating leukoencephalopathy in humans, and they demonstrate the critical importance of plasma membrane phosphoinositide homeostasis in myelin development and potentially 14 also in remyelination after myelin loss.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper
Plasmids and cloning. TTC7B-mCherry, mCherry-PI4KIIIα (NCBI NP_477352.3) and EFR3B-HA were previously described 5 , and PM-mCherry was obtained from the De Camilli laboratory. 3xFLAG-PI4KIIIα was generated by subcloning PI4KIIIα into the p3xFLAG-CMV-10 vector (Sigma) using NotI and EcoRI. TTC7B-3xFLAG was generated by subcloning TTC7B into the p3xFLAG-CMV-14 vector (Sigma) using HindIII and XbaI. EFR3B-BFP and TTC7B-BFP were generated by subcloning EFR3B into the pTagBFP-N vector (Evrogen) using XhoI and EcoRI (for EFR3B) and XhoI (for TTC7B). TTC7B-MYC was generated by subcloning TTC7B into the pCMV-MYC-N vector (Clontech) using XhoI and NotI. FAM126A (isoform 1, NM_032581.2) was obtained from Origene and subcloned into the pEGFP-N1 vector (Clontech) using XhoI and BamHI to make FAM126A-GFP. GFP-FAM126A-N and GFP-FAM126A-C were generated by subcloning FAM126A 1−289 and FAM126A 289−521 , respectively, into the pEGFP-C1 vector (Clontech) using KpnI and BamHI. For generation of stable HEK 293T cell lines, TTC7B-GFP, FAM126A-GFP and GFP were subcloned into the pCDNA5/FRT or pCDNA5/FRT/TO vectors (Thermo Fisher) using NheI and NotI (FRT, TTC7B-GFP), BamHI and XhoI (FRT/TO, FAM126A), or EcoRV and NotI (FRT/TO, GFP). The coding sequence for TTC7B 9−843 was cloned into a modified pCOLADuet-1 vector, which introduces an N-terminal dodeca-histidine-SUMO tag. The sequence for FAM126A 2−308 was cloned into pGEX-6P-1 (GE Healthcare). The sequence for the 419-amino-acid splice form of FAM126A (isoform 2, corresponding to NCBI XP_005249951.1) was synthesized as a gBlock (Integrated DNA Technologies) and cloned into the pEGFP-N1 vector using SalI and BamHI. This GFP-tagged alternate splice form, FAM126A 1−419 -GFP, was subcloned into the pLL3.7 lentiviral vector (Addgene plasmid no. 11795, gift from M. Higley, Yale University, USA) downstream of the CAG promoter at the EcoRI restriction site using the InFusion system (Clontech). The lentiviral packaging vectors pMD2.G and psPAX2 (Addgene no. 12259 and 12260) were kindly provided by D. Trono (Ecole Polytechnique Fédérale de Lausanne, Switzerland).
Antibodies. Working dilutions are listed in parentheses for all antibodies. An antibody against EFR3B (1:1,000) was previously reported 5 . Antibodies against mouse TTC7A (1:200) and mouse TTC7B (1:200) were generated by immunization of rabbits with KLH conjugates of the following peptides: Ac-CEASSPVLPFSIIAR EL-NH 2 (TTC7A); Ac-RLETEIERCRSECQWERIPELC-NH 2 (TTC7B) (Cocalico Biologicals). Sera were affinity purified using the antigenic peptide immobilized on SulfoLink resin, following the manufacturer's instructions (Thermo Fisher). An antibody against FAM126A (1:1,000) was generated by immunization of rabbits with a purified FAM126A fragment (residues 2-308), and sera were affinity purified by incubation with a nitrocellulose membrane onto which the FAM126A(2-308) fragment had been adsorbed, followed by elution with mild acid. The sources for the other antibodies are as follows: CNPase (1:1000, clone 11-5B, MAB326R, EMD Millipore), EFR3A (1:1,000, Ab2, Sigma), FAM126B (1:1,000, Novus Biologicals), FLAG (1:2,000, M2, Sigma), GAPDH (1:5,000, 1D4, Proteus Biosciences), GFP (1:5,000, Living Colors Monoclonal, Clontech), HA (1:5,000, 3F10, Roche), MBP (1:1,000, SMI 99, Covance), MYC (1:2,000, rabbit polyclonal, EMD Millipore), NeuN (1:1,000, clone A60, MAB377, EMD Millipore), human TTC7B (1:500, mouse IgG fraction, Sigma), PI4KIIIα (1:1,000, Cell Signaling Technology), PtdIns(4)P (1:100, Echelon), SYP (1:20,000, G95, Synaptic Systems), tubulin (1:10,000, B-5-1-2, Sigma).
Cell culture. All cells were grown at 37 • C in a 5% CO 2 atmosphere (except for Expi293 cells (obtained from Thermo Fisher), which were grown at 37 • C in an 8% CO 2 atmosphere, rotating at 125 r.p.m. on an orbital shaker) in cell culture medium (Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum and penicillin/streptomycin) and were tested to be negative for mycoplasma. HEK 293T cell lines stably expressing TTC7B-GFP, FAM126A-GFP or GFP were generated by transfection of Flp-In-293 cells (obtained from Thermo Fisher) with flippase (pOG44, Thermo Fisher) and either TTC7B-GFP, FAM126A or GFP in the pCDNA5/FRT or pCDNA5/FRT/TO vector, followed by selection according to the manufacturer's instructions (Thermo Fisher) using hygromycin B (Sigma). Stable HEK 293T cell lines were maintained in cell culture medium supplemented with 10 µg ml −1 hygromycin B. Stable HeLa cell lines expressing EFR3A-GFP, EFR3B-GFP or GFP were generated by transient transfection of HeLa cells (obtained from ATCC) followed by selection using G418 (Thermo Fisher), clonal isolation, and expansion. HEK 293 cell lines (parental cell lines for Expi293 and Flp-In-293 cells) and HeLa cells were validated by short tandem repeat profiling analysis by ATCC. HCC patient and control primary human skin fibroblasts (obtained from the Cell Line and DNA Biobank from Patients Affected by Genetic Diseases, Gaslini Institute) were described and validated previously 21, 27 . Following ethical guidelines, the samples were obtained for analysis and storage with written informed consent. Consent was sought using a form approved by the Gaslini Institute Ethics Committee. 
Immunoprecipitation and immunoblots. HEK 293T cells stably expressing
TTC7B-GFP, FAM126A-N-GFP or GFP were collected, resuspended in lysis buffer (150 mM NaCl, 20 mM Tris, 1 mM EDTA, 1% Triton X-100, pH 7.4, supplemented with protease inhibitors (cOmplete, EDTA-free (Roche))), sonicated briefly, and centrifuged for 10 min at 16,000g . The supernatant was immunoprecipitated in lysis buffer by addition of GFP-trap agarose (Chromotek) and rocking for 1 h at 4 • C. The resin was then isolated by centrifugation at 1,000g , rinsed three times with lysis buffer, and analysed either by SDS-PAGE, immunoblot (with detection by chemiluminescence), or mass spectrometry (see below). Original (uncropped) immunoblots are shown in Supplementary Fig. 6 .
Pulldown analysis by MS. Resin containing purified immunoprecipitates was rinsed three times with wash buffer (150 mM NaCl, 50 mM Tris, pH 7.4) and then denatured for 30 min with urea (8 M) in 0.1 M Tris, pH 7.4, 1 mM dithiothreitol before alkylation and pre-digestion with endoproteinase LysC (Wako Chemicals USA). After incubation for 3 h samples were diluted fourfold with ammonium bicarbonate (25 mM) and further digested with trypsin (Promega) overnight. Digestions were stopped by addition of trifluoroacetic acid (TFA, 1 µl) and the resulting peptides were loaded and desalted on C18 Stage Tips.
LC-MS/MS analysis.
Peptides were eluted from C18 Stage Tips with 60 µl of elution buffer (80% acetonitrile and 0.1% formic acid) and samples were dried down to 5 µl in a vacuum centrifuge. Peptides were then subjected to reversed phase chromatography on an Easy nLC 1000 system (Thermo Fisher Scientific) using a 50-cm column (New Objective) with an inner diameter of 75 µm, packed in-house with 1.9 µm C18 resin (Dr. Maisch). Peptides were eluted with an acetonitrile gradient (5-30% for 95 min at a constant flow rate of 250 nl min −1 ) and directly electrosprayed into a mass spectrometer (Q Exactive; Thermo Fisher Scientific). Mass spectra were acquired on the spectrometer in a data-dependent mode to automatically switch between full-scan MS and up to 10 data-dependent MS/MS scans. The maximum injection time for full scans was 20 ms, with a target value of 3,000,000 at a resolution of 70,000 at m/z = 200. The ten most intense multiple charged ions (z ≥ 2) from the survey scan were selected with an isolation width of 3 Th and fragmented with higher-energy collision dissociation (HCD) with normalized collision energies of 25. Target values for MS/MS were set to 1,000,000 with a maximum injection time of 120 ms at a resolution of 17,500 at m/z = 200. To avoid repetitive sequencing, the dynamic exclusion of sequenced peptides was set to 20 s. MS data analysis. MS and MS/MS spectra were analysed using MaxQuant (version 1.4.0.5), using its integrated ANDROMEDA search algorithms 32 . Scoring of peptides for identification was carried out with an initial allowed mass deviation of the precursor ion of up to 6 ppm for the search for peptides with a minimum length of six amino acids. The allowed fragment mass deviation was 20 ppm. The false discovery rate (FDR) was set to 0.01 for proteins and peptides. Peak lists were searched against a local database for human proteome. Maximum missed cleavages were set to 2. The search included carbamidomethylation of cysteines as a fixed modification and methionine oxidation and N-terminal acetylation as variable modifications. All calculations and plots were performed as described previously 33 using the R software package.
Imaging. For live-cell imaging, cells were grown in glass-bottom dishes (no. 1.5 thickness, MatTek Corporation). For immunofluorescence, cells were grown on cover slips (no. 1 thickness, neuVitro). Immunofluorescence labelling for PtdIns(4)P was performed as previously described 34 . Imaging experiments were performed on a spinning-disc confocal microscope, using the PerkinElmer UltraVIEW VoX system including a Nikon Ti-E Eclipse inverted microscope equipped with Perfect Focus, a temperature-controlled stage, a 14-bit electron-multiplying CCD (chargecoupled device) camera (Hamamatsu C9100-50), and a spinning-disc confocal scan head (CSU-X1, Yokogawa) controlled by Volocity software (PerkinElmer). All images were acquired through a 60× or 100× oil objective (1.4 NA, CFI Plan Apo VC). Blue fluorescence was excited with a 405 nm/50 mW diode laser (Melles Griot) and collected by a BP 445/60 filter. Green fluorescence was excited with a 488 nm/50 mW diode laser (Coherent) and collected by a BP 527/55 filter. Red fluorescence was excited with a 561 nm/50 mW diode laser (Cobolt) and collected by a BP 615/70 filter. Multicolour images were acquired sequentially. Image acquisition was performed using the Volocity software (PerkinElmer) and image analysis was performed using Fiji. For the quantification of plasma membrane PtdIns(4)P immunofluorescence, samples were blinded, and average intensity and incubated with the cell-specific beads for 15 min. The cells were then loaded on LS columns and separated on a quadroMACS magnet, first with anti-O4 beads (elution was labelled oligodendrocyte lineage), and then with anti-ACSA beads to deplete astrocytes, and the remainder (flow-through) was a sample enriched in cells of the neuronal lineage. The target cells were washed once in PBS, then pelleted and snap-frozen. Pellets were subsequently thawed, and lysates were generated for immunoblot analysis.
Light and electron microscopic imaging of myelin in FAM126A KO mice.
Male mice at age P15 (three FAM126A KO and two littermate WT controls, on a mixed 129/C57BL/6 background) were perfused transcardially with 2% paraformaldehyde, 2.5% glutaraldehyde in 100 mM cacodylate buffer pH 7.4. Samples were postfixed with 1% osmium tetroxide, 1.5% potassium ferrocyanide in 100 mM cacodylate buffer pH 7.4, en bloc stained with uranyl acetate, dehydrated in increasing concentrations of ethanol and propylene oxide, and finally embedded in Epon. Samples were cured at 60 • C in an oven for 48 h. Epon blocks were sectioned using a Leica EM UC7 ultramicrotome (Leica Microsystems). For light microscopy, semithin sections (1 µm) of optic nerve, corpus callosum (sagittal section of the central area), and spinal cord (ventral funiculus cervical region) were generated and stained with toluidine blue. Light microscopy was performed on a Zeiss Axio Imager equipped with a Plan-Apochromat 100×/1.4 oil objective with an AxioCam MRc 5 colour CCD camera. For electron microscopy, ultrathin sections (60 nm) were contrasted with 2% uranyl acetate and Sato's lead solutions and observed with a LEO 912AB Zeiss Transmission Electron Microscope (Carl Zeiss). Digital micrographs were taken with a 2k × 2k bottom-mounted slowscan Proscan camera (ProScan) controlled by the EsivisionPro 3.2 software (Soft Imaging System).
Statistics and reproducibility. Statistical analysis was performed using either
Microsoft Excel or Prism 6 software. Detailed statistical information (which statistical test was used, number of independent experiments, P values, definition of error bars) is listed in individual figure legends. All immunoblots were repeated at least three times except for some immunoblots shown in Fig. 5 , which were repeated twice (see legend for Supplementary Fig. 4a for details) . All imaging experiments were repeated three times. No statistical method was used to predetermine samples size for animal experiments, and the experiments were not randomized.
